β-Lactamase cleavable antimicrobial peptide-drug conjugates

Area of Science:

• Microbiology
• Medicinal Chemistry
• Drug Discovery

Background:

• Antimicrobial resistance (AMR) poses a significant global health threat, diminishing the efficacy of existing antibacterial treatments.
• There is an urgent need for novel therapeutic strategies to overcome bacterial resistance mechanisms.
• Current approaches focus on responsible antibiotic use and the development of new drugs.

Purpose of the Study:

• To develop and evaluate a novel cleavable peptide-drug conjugate for targeting bacteria with diverse resistance mechanisms.
• To investigate the components and activity of the conjugate for potential therapeutic applications against resistant bacterial infections.

Main Methods:

• Design and synthesis of a peptide-drug conjugate comprising a β-lactamase cleavable linker, a stapled antimicrobial peptide, and an antibiotic.
• Investigation of conjugate activity, including cleavage by β-lactamase and determination of minimal inhibitory concentrations (MICs).
• Comparison of the cleavable conjugate's potency against a non-cleavable control.

Main Results:

• The synthesized conjugate demonstrated selective cleavage by β-lactamase.
• The cleavable peptide-drug conjugate exhibited superior antimicrobial potency compared to its non-cleavable counterpart.
• Minimal inhibitory concentrations indicated enhanced efficacy against resistant bacterial strains.

Conclusions:

• Cleavable peptide-drug conjugates represent a viable strategy for combating antimicrobial resistance.
• The designed conjugate, featuring a cleavable linker and stapled peptide, shows promise for treating infections caused by resistant bacteria.
• This approach offers a dual mode of action to reduce resistance development and potentially lower systemic toxicity.